Treatment Effects on Development of Chemotherapy-Induced Peripheral Neuropathy in Patients With Cancer

• Sponsor: Southwest Oncology Group (Other)
• Overall Status: Active, not recruiting
• CT.gov ID: NCT03939481
• Collaborator: National Cancer Institute (NCI) (NIH)
• Enrollment: 1,336
• Locations: 169
• Anticipated Duration (Months): 84
• Patients Per Site: 7.9
• Patients Per Site Per Month: 0.1

Study Details

Study Description

Brief Summary

This trial studies treatment effects on development of chemotherapy-induced peripheral neuropathy in patients with cancer. Treatments for cancer can cause a problem to the nervous system (called peripheral neuropathy) that can lead to tingling or less feeling in hands and feet. Studying certain risk factors, such as age, gender, pre-existing conditions, and the type of treatment for cancer may help doctors estimate how likely patients are to develop the nerve disorder.

Condition or Disease	Intervention/Treatment	Phase
Anatomic Stage I Breast Cancer AJCC v8; Anatomic Stage IA Breast Cancer AJCC v8; Anatomic Stage IB Breast Cancer AJCC v8; Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage IIA Breast Cancer AJCC v8; Anatomic Stage IIB Breast Cancer AJCC v8; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIB Breast Cancer AJCC v8; Anatomic Stage IIIC Breast Cancer AJCC v8; Lung Non-Small Cell Carcinoma; Prognostic Stage I Breast Cancer AJCC v8; Prognostic Stage IA Breast Cancer AJCC v8; Prognostic Stage IB Breast Cancer AJCC v8; Prognostic Stage II Breast Cancer AJCC v8; Prognostic Stage IIA Breast Cancer AJCC v8; Prognostic Stage IIB Breast Cancer AJCC v8; Prognostic Stage III Breast Cancer AJCC v8; Prognostic Stage IIIA Breast Cancer AJCC v8; Prognostic Stage IIIB Breast Cancer AJCC v8; Prognostic Stage IIIC Breast Cancer AJCC v8; Stage I Lung Cancer AJCC v8; Stage I Ovarian Cancer AJCC v8; Stage IA Ovarian Cancer AJCC v8; Stage IA1 Lung Cancer AJCC v8; Stage IA2 Lung Cancer AJCC v8; Stage IA3 Lung Cancer AJCC v8; Stage IB Lung Cancer AJCC v8; Stage IB Ovarian Cancer AJCC v8; Stage IC Ovarian Cancer AJCC v8; Stage II Lung Cancer AJCC v8; Stage II Ovarian Cancer AJCC v8; Stage IIA Lung Cancer AJCC v8; Stage IIA Ovarian Cancer AJCC v8; Stage IIB Lung Cancer AJCC v8; Stage IIB Ovarian Cancer AJCC v8; Stage III Lung Cancer AJCC v8; Stage III Ovarian Cancer AJCC v8; Stage IIIA Lung Cancer AJCC v8; Stage IIIA Ovarian Cancer AJCC v8; Stage IIIA1 Ovarian Cancer AJCC v8; Stage IIIA2 Ovarian Cancer AJCC v8; Stage IIIB Lung Cancer AJCC v8; Stage IIIB Ovarian Cancer AJCC v8; Stage IIIC Lung Cancer AJCC v8; Stage IIIC Ovarian Cancer AJCC v8	Drug: Chemotherapy; Other: Functional Assessment; Other: Questionnaire Administration

Detailed Description

PRIMARY OBJECTIVES:

1. To develop and validate a clinical risk prediction model using clinical factors for the development of peripheral neuropathy in patients receiving taxane-based chemotherapy regimens.

SECONDARY OBJECTIVES:

1. To examine patient-reported outcomes (PROs) and objective measures of chemotherapy induced peripheral neuropathy (CIPN) to better define the phenotype of peripheral neuropathy in this patient population.

2. To assess the incidence of CIPN within one year in this patient population. III. To identify predictors of treatment dose reductions, delays, and discontinuations associated with CIPN symptoms in this patient population.

OTHER OBJECTIVES:

1. To collect serum and plasma samples for future testing for biomarker and mechanistic studies of CIPN.

OUTLINE:

Patients receive chemotherapy regimen per treating physician for 52 weeks in the absence of disease progression or unacceptable toxicity. Patients also complete questionnaires at weeks 4, 8, 12, 24 and 52.

Study Design

• Study Type: Observational
• Actual Enrollment: 1336 participants
• Observational Model: Cohort
• Time Perspective: Prospective
• Official Title: A Prospective Observational Cohort Study to Develop a Predictive Model of Taxane-Induced Peripheral Neuropathy in Cancer Patients
• Actual Study Start Date: Mar 1, 2019
• Anticipated Primary Completion Date: Feb 28, 2025
• Anticipated Study Completion Date: Feb 28, 2026

Arms and Interventions

Arm	Intervention/Treatment
Observational (non-study chemo, questionnaire, assessments) Patients receive chemotherapy regimen per treating physician for 52 weeks in the absence of disease progression or unacceptable toxicity. Patients also complete questionnaires at weeks 4, 8, 12, 24 and 52.	Drug: Chemotherapy; Given chemotherapy regimen; Other Names: Chemo Chemotherapy (NOS) Chemotherapy, Cancer, General ; Other: Functional Assessment; Functional and sensory clinician assessments; Other: Questionnaire Administration; Patient and physician reported responses

Outcome Measures

Primary Outcome Measures

1. Development of peripheral neuropathy [Up to 24 weeks]

   Will be measured as an absolute increase of >= 8 points over the baseline chemotherapy-induced peripheral neuropathy (CIPN)-20 sensory neuropathy subscale score. Will be collected before or at the 24-week assessment as the taxane-based chemotherapy regimens in this study are expected to be completed within 8 to 18 weeks. The presence of CIPN will be captured at 52 weeks to evaluate the duration of neuropathy which is anticipated to wane after treatment discontinuation.

Secondary Outcome Measures

1. CIPN symptoms [Up to 52 weeks]

   Patients experiencing a treatment change attributed to CIPN symptoms

2. Dose Changes [Up to 52 weeks]

   Dose reductions, delays, and discontinuations of treatment (prior to completing the original treatment plan)

3. Health-related Quality of Life [Up to 52 weeks]

   Assessed using the Patient-Reported Outcomes Measurement Information System 29 (PROMIS-29). The PROMIS-29 is a well validated assessment tool that offers both qualitative and quantitative measures of health-related quality of life. The PROMIS-29 includes 29 questions evaluating areas of physical function, anxiety, depression, fatigue, sleep, social functioning, and pain interference. The PROMIS-29 assesses severity levels of symptoms and their effect on the patient's functioning.

4. Visual Analog Toxicity Score [Up to 52 weeks]

   Assessed using the Visual Analog Toxicity Score. The Visual Analog Toxicity Score is a single question asking the physician to rate how the physician feels the patient's disease and treatment affects their daily life on a scale from 0 (no symptoms and no effect on life) to 10 (severe effects of treatment and patient would rather be dead).

5. Patient Reported Symptom [Up to 52 weeks]

   Assessed using the Patient Reported Symptom Burden Score. The Patient Reported Symptom Score at baseline contains one question to assess how cancer symptoms affect the patient's life (scale 0 [no burden at all] to 10 [a great burden]). At follow-up, the Symptom Burden Score contains five questions: 1) to assess burden of side effects of cancer treatment on life (scale 0 [no burden at all] to 10 [a great burden]), 2) to assess severity of side effects from cancer treatment (scale 0 [no side effects]) to 10 [side effects extremely severe and unbearable]), 3) to assess tolerability of side effects for set time periods (yes/no), 4) to assess level at which treatment would be considered intolerable (scale 0 [side effects not severe at all] to 10 [side effects extremely severe and unbearable]), and 5) to assess the burden of cancer symptoms and treatment symptoms (scale 0 [no burden at all] to 10 [a great burden]).

6. Leisure-time Exercise Habits [Up to 52 weeks]

   Assessed using the Godin-Shephard Leisure-Time Physical Activity Questionnaire (GSLTPAQ). The GSLTPAQ is a brief 4 item self-administered questionnaire of usual leisure-time exercise habits over a typical 7-day period. The Leisure Score Index (LSI) is calculated based on the first 3 questions. The LSI scores can be used to classify respondents into active (LSI > 24) and insufficiently active (LSI < 23) categories.

7. Patient-Reported Outcomes [Up to 52 weeks]

   Assessed using the Patient Reported Outcomes Common Terminology Criteria for Adverse Events (PRO-CTCAE [CTCAE Version 5.0]). PRO-CTCAE assesses 78 adverse events by self-report with 124 items. Each item uses a plain language term for the adverse event, the attribute of interest, and the standard recall period of "the past 7 days".

8. National Cancer Institute-Common Terminology Criteria for Adverse Events [Up to 52 weeks]

   The NCI-CTCAE is a subjective method to evaluate CIPN performed by a healthcare professional. The treating physician will grade the subject's dysesthesia, paresthesia, neuralgia, peripheral sensory neuropathy, and peripheral motor neuropathy on a scale of 0 to 5 depending on the severity. The advantage of the NCI-CTCAE is that the assessment is quick and easy for providers to perform, (8) but it is limited by the subjectivity of interpretation, lack of detail about location, type, and severity of impairment, and narrow scoring range.

9. Assess incidence of CIPN [Up to 52 weeks]

   Assessed using European Organization for Research and Treatment of Cancer (EORTC) QLQ-CIPN20 (CIPN-20). The EORTC QLQ-CIPN20 is a 20-item questionnaire that evaluates CIPN using 3 subscales that assess sensory (9 items), motor (8 items), and autonomic (3 items) symptoms and functioning with each item measured on a 1-4 scale (1, not at all; 4, very much). The sensory subscale raw scores range from 1 to 36. The CIPN-20 subscale raw scores are linearly converted to a 0-100 scale such that a high score corresponds to a worse condition or more symptoms.

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

• Patients must have stage I, II, or III primary non-small cell lung, primary breast, or primary ovarian cancer based on clinical or pathologic evaluation. Patients with Stage IV disease are not eligible.

• Patients must be planning to start treatment with a taxane-based chemotherapy as part of one of the study-approved taxane regimens (docetaxel chemotherapy regimens for treatment of breast or ovarian cancer, or paclitaxel chemotherapy regimen for treatment of breast, non-small cell lung, or ovarian cancer) within 14 days after registration. (Note that docetaxel or paclitaxel may be administered with a non-neurotoxic chemotherapy, such as cyclophosphamide, and/or biologic agent, such as trastuzumab, and/or carboplatin. Additionally, nab-paclitaxel may not be substituted for paclitaxel for purposes of this study.)

• Patients who will receive treatment in the setting of any other clinical trial are eligible as long as it is one of the study-approved regimens. Patients may receive additional treatments (i.e., experimental therapy, immunotherapy, biologics, etc.) as part of another clinical trial in addition to any regimen approved in this study.

• Patients must not have received a taxane (paclitaxel, docetaxel, or protein-bound paclitaxel), platinum (cisplatin, carboplatin, or oxaliplatin), vinca alkaloid (vinblastine, vincristine, or vinorelbine), or bortezomib-based chemotherapy regimen prior to registration. (Note that while patients must not have received carboplatin in the past, patients may receive a carboplatin-containing regimen after registration as part of the docetaxel or paclitaxel regimen.)

• Patients who can complete Patient-Reported Outcome (PRO) instruments in English or

Spanish must:

• Agree to complete PROs at all scheduled assessments

• Complete the baseline PRO forms prior to registration

• Patients with pre-existing neuropathy are eligible, including those with diabetes and neurological conditions such as multiple sclerosis or Parkinson?s disease.

• Patients must agree to submit required specimens for defined translational medicine.

• Patients must be offered the opportunity to submit additional optional specimens for future, unspecified translational medicine and banking. With patient?s consent, specimens must be submitted.

• Patients must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines.

• As a part of the OPEN registration process the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Kaiser Permanente-Deer Valley Medical Center	Antioch	California	United States	94531
2	Kaiser Permanente Dublin	Dublin	California	United States	94568
3	Kaiser Permanente-Fremont	Fremont	California	United States	94538
4	Kaiser Permanente-Fresno	Fresno	California	United States	93720
5	Kaiser Permanente-Oakland	Oakland	California	United States	94611
6	Desert Regional Medical Center	Palm Springs	California	United States	92262
7	Kaiser Permanente-San Francisco	San Francisco	California	United States	94115
8	Kaiser Permanente-Santa Teresa-San Jose	San Jose	California	United States	95119
9	Kaiser Permanente San Leandro	San Leandro	California	United States	94577
10	Kaiser San Rafael-Gallinas	San Rafael	California	United States	94903
11	Kaiser Permanente Medical Center - Santa Clara	Santa Clara	California	United States	95051
12	Kaiser Permanente-Santa Rosa	Santa Rosa	California	United States	95403
13	Kaiser Permanente Medical Center-Vacaville	Vacaville	California	United States	95688
14	Kaiser Permanente-Vallejo	Vallejo	California	United States	94589
15	Kaiser Permanente-Walnut Creek	Walnut Creek	California	United States	94596
16	Rocky Mountain Regional VA Medical Center	Aurora	Colorado	United States	80045
17	Bayhealth Hospital Kent Campus	Dover	Delaware	United States	19901
18	Bayhealth Hospital Sussex Campus	Milford	Delaware	United States	19963
19	Florida Gynecologic Oncology	Fort Myers	Florida	United States	33905
20	Regional Cancer Center-Lee Memorial Health System	Fort Myers	Florida	United States	33905
21	Sacred Heart Hospital	Pensacola	Florida	United States	32504
22	Lewis Cancer and Research Pavilion at Saint Joseph's/Candler	Savannah	Georgia	United States	31405
23	Hawaii Cancer Care - Savio	'Aiea	Hawaii	United States	96701
24	Pali Momi Medical Center	'Aiea	Hawaii	United States	96701
25	Hawaii Cancer Care Inc - Waterfront Plaza	Honolulu	Hawaii	United States	96813
26	Straub Clinic and Hospital	Honolulu	Hawaii	United States	96813
27	University of Hawaii Cancer Center	Honolulu	Hawaii	United States	96813
28	Kaiser Permanente Moanalua Medical Center	Honolulu	Hawaii	United States	96819
29	Kapiolani Medical Center for Women and Children	Honolulu	Hawaii	United States	96826
30	Wilcox Memorial Hospital and Kauai Medical Clinic	Lihue	Hawaii	United States	96766
31	Centralia Oncology Clinic	Centralia	Illinois	United States	62801
32	Carle on Vermilion	Danville	Illinois	United States	61832
33	Cancer Care Specialists of Illinois - Decatur	Decatur	Illinois	United States	62526
34	Decatur Memorial Hospital	Decatur	Illinois	United States	62526
35	Carle Physician Group-Effingham	Effingham	Illinois	United States	62401
36	Crossroads Cancer Center	Effingham	Illinois	United States	62401
37	Little Company of Mary Hospital	Evergreen Park	Illinois	United States	60805
38	Edward Hines Jr VA Hospital	Hines	Illinois	United States	60141
39	Carle Physician Group-Mattoon/Charleston	Mattoon	Illinois	United States	61938
40	Trinity Medical Center	Moline	Illinois	United States	61265
41	Cancer Care Center of O'Fallon	O'Fallon	Illinois	United States	62269
42	Carle Cancer Center	Urbana	Illinois	United States	61801
43	The Carle Foundation Hospital	Urbana	Illinois	United States	61801
44	McFarland Clinic PC - Ames	Ames	Iowa	United States	50010
45	Physicians' Clinic of Iowa PC	Cedar Rapids	Iowa	United States	52402
46	Mercy Hospital	Cedar Rapids	Iowa	United States	52403
47	Oncology Associates at Mercy Medical Center	Cedar Rapids	Iowa	United States	52403
48	Medical Oncology and Hematology Associates-West Des Moines	Clive	Iowa	United States	50325
49	Mercy Cancer Center-West Lakes	Clive	Iowa	United States	50325
50	Greater Regional Medical Center	Creston	Iowa	United States	50801
51	Iowa Methodist Medical Center	Des Moines	Iowa	United States	50309
52	Medical Oncology and Hematology Associates-Des Moines	Des Moines	Iowa	United States	50309
53	Broadlawns Medical Center	Des Moines	Iowa	United States	50314
54	Medical Oncology and Hematology Associates-Laurel	Des Moines	Iowa	United States	50314
55	Mercy Medical Center - Des Moines	Des Moines	Iowa	United States	50314
56	Mercy Medical Center-West Lakes	West Des Moines	Iowa	United States	50266
57	HaysMed University of Kansas Health System	Hays	Kansas	United States	67601
58	Lawrence Memorial Hospital	Lawrence	Kansas	United States	66044
59	Olathe Health Cancer Center	Olathe	Kansas	United States	66061
60	Salina Regional Health Center	Salina	Kansas	United States	67401
61	University of Kansas Health System Saint Francis Campus	Topeka	Kansas	United States	66606
62	Associates In Womens Health	Wichita	Kansas	United States	67208
63	Cancer Center of Kansas-Wichita Medical Arts Tower	Wichita	Kansas	United States	67208
64	Cancer Center of Kansas - Wichita	Wichita	Kansas	United States	67214
65	Flaget Memorial Hospital	Bardstown	Kentucky	United States	40004
66	Saint Joseph Hospital East	Lexington	Kentucky	United States	40509
67	Saint Joseph London	London	Kentucky	United States	40741
68	Louisiana State University Health Science Center	New Orleans	Louisiana	United States	70112
69	Tulane University Health Sciences Center	New Orleans	Louisiana	United States	70112
70	University Medical Center New Orleans	New Orleans	Louisiana	United States	70112
71	LSU Health Sciences Center at Shreveport	Shreveport	Louisiana	United States	71103
72	Harold Alfond Center for Cancer Care	Augusta	Maine	United States	04330
73	Waldo County General Hospital	Belfast	Maine	United States	04915
74	MaineHealth/SMHC Cancer Care and Blood Disorders-Biddeford	Biddeford	Maine	United States	04005
75	Penobscot Bay Medical Center	Rockport	Maine	United States	04856
76	MaineHealth/SMHC Cancer Care and Blood Disorders-Sanford	Sanford	Maine	United States	04073
77	Maine Medical Center- Scarborough Campus	Scarborough	Maine	United States	04074
78	Greater Baltimore Medical Center	Baltimore	Maryland	United States	21204
79	University of Maryland Shore Medical Center at Easton	Easton	Maryland	United States	21601
80	Lahey Hospital and Medical Center	Burlington	Massachusetts	United States	01805
81	Winchester Hospital	Winchester	Massachusetts	United States	01890
82	Mercy Health Saint Mary's	Grand Rapids	Michigan	United States	49503
83	Spectrum Health at Butterworth Campus	Grand Rapids	Michigan	United States	49503
84	Spectrum Health Reed City Hospital	Reed City	Michigan	United States	49677
85	Munson Medical Center	Traverse City	Michigan	United States	49684
86	Metro Health Hospital	Wyoming	Michigan	United States	49519
87	Fairview Ridges Hospital	Burnsville	Minnesota	United States	55337
88	Minnesota Oncology - Burnsville	Burnsville	Minnesota	United States	55337
89	Mercy Hospital	Coon Rapids	Minnesota	United States	55433
90	Essentia Health - Deer River Clinic	Deer River	Minnesota	United States	56636
91	Essentia Health Cancer Center	Duluth	Minnesota	United States	55805
92	Fairview Southdale Hospital	Edina	Minnesota	United States	55435
93	Unity Hospital	Fridley	Minnesota	United States	55432
94	Essentia Health Hibbing Clinic	Hibbing	Minnesota	United States	55746
95	Fairview Clinics and Surgery Center Maple Grove	Maple Grove	Minnesota	United States	55369
96	Minnesota Oncology Hematology PA-Maplewood	Maplewood	Minnesota	United States	55109
97	Saint John's Hospital - Healtheast	Maplewood	Minnesota	United States	55109
98	Abbott-Northwestern Hospital	Minneapolis	Minnesota	United States	55407
99	Hennepin County Medical Center	Minneapolis	Minnesota	United States	55415
100	Monticello Cancer Center	Monticello	Minnesota	United States	55362
101	North Memorial Medical Health Center	Robbinsdale	Minnesota	United States	55422
102	Park Nicollet Clinic - Saint Louis Park	Saint Louis Park	Minnesota	United States	55416
103	Regions Hospital	Saint Paul	Minnesota	United States	55101
104	United Hospital	Saint Paul	Minnesota	United States	55102
105	Essentia Health Sandstone	Sandstone	Minnesota	United States	55072
106	Lakeview Hospital	Stillwater	Minnesota	United States	55082
107	Essentia Health Virginia Clinic	Virginia	Minnesota	United States	55792
108	Rice Memorial Hospital	Willmar	Minnesota	United States	56201
109	Minnesota Oncology Hematology PA-Woodbury	Woodbury	Minnesota	United States	55125
110	Fairview Lakes Medical Center	Wyoming	Minnesota	United States	55092
111	Mercy Clinic-Rolla-Cancer and Hematology	Rolla	Missouri	United States	65401
112	Missouri Baptist Medical Center	Saint Louis	Missouri	United States	63131
113	Mercy Hospital Springfield	Springfield	Missouri	United States	65804
114	CHI Health Saint Francis	Grand Island	Nebraska	United States	68803
115	Saint Joseph Hospital	Nashua	New Hampshire	United States	03060
116	NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center	New York	New York	United States	10032
117	Randolph Hospital	Asheboro	North Carolina	United States	27203
118	AdventHealth Infusion Center Asheville	Asheville	North Carolina	United States	28803
119	Cone Health Cancer Center at Alamance Regional	Burlington	North Carolina	United States	27215
120	Southeastern Medical Oncology Center-Clinton	Clinton	North Carolina	United States	28328
121	AdventHealth Infusion Center Haywood	Clyde	North Carolina	United States	28721
122	CaroMont Regional Medical Center	Gastonia	North Carolina	United States	28054
123	Southeastern Medical Oncology Center-Goldsboro	Goldsboro	North Carolina	United States	27534
124	Cone Health Cancer Center	Greensboro	North Carolina	United States	27403
125	AdventHealth Hendersonville	Hendersonville	North Carolina	United States	28792
126	Southeastern Medical Oncology Center-Jacksonville	Jacksonville	North Carolina	United States	28546
127	CarolinaEast Medical Center	New Bern	North Carolina	United States	28561
128	FirstHealth of the Carolinas-Moore Regional Hospital	Pinehurst	North Carolina	United States	28374
129	Nash General Hospital	Rocky Mount	North Carolina	United States	27804
130	NHRMC Radiation Oncology - Supply	Supply	North Carolina	United States	28462
131	New Hanover Regional Medical Center/Zimmer Cancer Center	Wilmington	North Carolina	United States	28401
132	Trinity Cancer Care Center	Minot	North Dakota	United States	58701
133	Cleveland Clinic Akron General	Akron	Ohio	United States	44307
134	Good Samaritan Hospital - Cincinnati	Cincinnati	Ohio	United States	45220
135	Kaiser Permanente Northwest	Portland	Oregon	United States	97227
136	Phoenixville Hospital	Phoenixville	Pennsylvania	United States	19460
137	Kent Hospital	Warwick	Rhode Island	United States	02886
138	AnMed Health Cancer Center	Anderson	South Carolina	United States	29621
139	Saint Joseph's/Candler - Bluffton Campus	Bluffton	South Carolina	United States	29910
140	Prisma Health Cancer Institute - Spartanburg	Boiling Springs	South Carolina	United States	29316
141	McLeod Regional Medical Center	Florence	South Carolina	United States	29506
142	Gibbs Cancer Center-Gaffney	Gaffney	South Carolina	United States	29341
143	Saint Francis Hospital	Greenville	South Carolina	United States	29601
144	Prisma Health Cancer Institute - Butternut	Greenville	South Carolina	United States	29605
145	Prisma Health Cancer Institute - Faris	Greenville	South Carolina	United States	29605
146	Saint Francis Cancer Center	Greenville	South Carolina	United States	29607
147	Prisma Health Cancer Institute - Eastside	Greenville	South Carolina	United States	29615
148	Prisma Health Cancer Institute - Greer	Greer	South Carolina	United States	29650
149	Gibbs Cancer Center-Pelham	Greer	South Carolina	United States	29651
150	South Carolina Cancer Specialists PC	Hilton Head Island	South Carolina	United States	29926-3827
151	Prisma Health Cancer Institute - Seneca	Seneca	South Carolina	United States	29672
152	Spartanburg Medical Center	Spartanburg	South Carolina	United States	29303
153	MGC Hematology Oncology-Union	Union	South Carolina	United States	29379
154	Cookeville Regional Medical Center	Cookeville	Tennessee	United States	38501
155	Ballad Health Cancer Care - Kingsport	Kingsport	Tennessee	United States	37660
156	UMC Cancer Center / UMC Health System	Lubbock	Texas	United States	79415
157	Texas Tech University Health Sciences Center-Lubbock	Lubbock	Texas	United States	79430
158	Wellmont Medical Associates-Bristol	Bristol	Virginia	United States	24201
159	University of Virginia Cancer Center	Charlottesville	Virginia	United States	22908
160	Bon Secours Memorial Regional Medical Center	Mechanicsville	Virginia	United States	23116
161	Bon Secours Saint Francis Medical Center	Midlothian	Virginia	United States	23114
162	Bon Secours Saint Mary's Hospital	Richmond	Virginia	United States	23226
163	Swedish Cancer Institute-Issaquah	Issaquah	Washington	United States	98029
164	Jefferson Healthcare	Port Townsend	Washington	United States	98368
165	Duluth Clinic Ashland	Ashland	Wisconsin	United States	54806
166	Cancer Center of Western Wisconsin	New Richmond	Wisconsin	United States	54017
167	Instituto Nacional del Cancer	Independence		Chile	8380455
168	Instituto Nacional De Cancerologia	Bogota		Colombia	99999
169	Instituto Nacional De Cancerologia de Mexico	Mexico City	Tlalpan	Mexico	14080

Sponsors and Collaborators

• Southwest Oncology Group
• National Cancer Institute (NCI)

Investigators

• Principal Investigator: Meghna S Trivedi, Southwest Oncology Group

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Southwest Oncology Group
• ClinicalTrials.gov Identifier: NCT03939481
• Other Study ID Numbers: S1714; NCI-2018-01568; S1714; SWOG-S1714; S1714; UG1CA189974
• First Posted: May 6, 2019
• Last Update Posted: May 5, 2022
• Last Verified: May 1, 2022

• Additional relevant MeSH terms: Breast Neoplasms; Lung Neoplasms; Ovarian Neoplasms; Carcinoma, Ovarian Epithelial; Carcinoma, Non-Small-Cell Lung; Peripheral Nervous System Diseases

Study Results

No Results Posted as of May 5, 2022